Effect of insulin resistance on left ventricular remodelling in essential hypertensives: a cross-sectional study

Bernard Kianu Phanzu1, Aliocha Nkodila Natuhoyila2, Eleuthère Kintoki Vita3

  • 1Department of Internal Medicine, Division of Cardiology, University of Kinshasa Hospital, Kinshasa, Democratic Republic of the Congo; Centre Médical de Kinshasa, Kinshasa, Democratic Republic of the Congo.

Insights

Insulin resistance and hyperinsulinaemia impact left ventricular hypertrophy differently. Insulin resistance affects left ventricular end-diastolic diameter, while hyperinsulinaemia impacts posterior wall thickness, both contributing to diastolic dysfunction.

Area of Science:

  • Cardiology
  • Endocrinology
  • Internal Medicine

Background:

  • Left ventricular hypertrophy (LVH) is clinically assessed using imperfect physical and electrocardiographic criteria.
  • Echocardiography defines LVH by left ventricular mass, calculated using Devereux's formula, which is influenced by insulin resistance and hyperinsulinaemia.
  • The distinct roles of insulin resistance and hyperinsulinaemia in LVH development and diastolic dysfunction remain unclear.

Purpose of the Study:

  • To evaluate the associations of insulin resistance (using homeostatic model assessment for insulin resistance - HOMAIR) and fasting plasma insulin levels with Devereux's formula components and left ventricular diastolic function parameters.
  • To elucidate the specific contributions of insulin resistance and hyperinsulinaemia to left ventricular geometry and diastolic function in hypertensive patients.

Main Methods:

  • Collected clinical data from 220 hypertensive patients.
  • Utilized logistic regression models to test associations between insulin resistance markers (HOMAIR, fasting insulin) and Devereux's formula components and diastolic function parameters.

Main Results:

  • Insulin level and HOMAIR explained 46.8% of interventricular septum diameter variation and 30.9% of E-wave deceleration time variation.
  • HOMAIR alone explained 30.1% of left ventricular end-diastolic diameter variation.
  • Insulin level alone explained 46.3% of posterior wall thickness and 29.4% of relative wall thickness variation.

Conclusions:

  • Insulin resistance and hyperinsulinaemia exert differential effects on left ventricular hypertrophy components.
  • Insulin resistance influences left ventricular end-diastolic diameter, while hyperinsulinaemia affects posterior wall thickness.
  • Both insulin resistance and hyperinsulinaemia contribute to interventricular septum changes and diastolic dysfunction.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
17
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
19
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15